New Search

Export article

Immunosuppressants in Behcet’s disease: a boon or a bane?

Krishna Modi, Vipul Prajapati, Dhaiwat Shukla, Supriya D. Malhotra

Abstract: Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by antagonising tumour necrosis factor-alpha prescribed in many rheumatological conditions like Rheumatic arthritis, Ankylosing spondylitis and Behcet’s disease. Serious side effects with this drug include heart and liver failure, nervous and blood disorders, allergic and immune system reactions and opportunistic infections. A 27-year-old female patient, known case of Behcet’s disease presented to the hospital with complaints of fever, cough and breathlessness following administration of Adalimumab, six doses over three months. Chest X-ray and BAL-CBNAAT was suggestive of Tuberculosis. AKT was started and Adalimumab was suspended until patient recover.
Keywords: Behcet / antibody / Adalimumab / Rheumatic arthritis / Ankylosing spondylitis / female patient / known case / modifying antirheumatic / disease presented / include heart

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "International Journal of Basic & Clinical Pharmacology" .
Back to Top Top